November 2013 Editor's Picks: Products from Pall and I Holland - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

November 2013 Editor's Picks: Products from Pall and I Holland
Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Pall
A single-use system provides flexible automation for biopharmaceutical manufacturing.

The Allegro MVP system from Pall is a fully automated platform that can be used across a range of upstream and downstream bioprocessing activities. A manifold selection tool facilitates selection of sensors, connectors, tubing type, filters, and prefilters needed for each application. Intuitive, easy-to-read labels on the manifold sets ease installation. The fully automated MVP system provides reliable control of process conditions and monitoring of all process variables, and the use of automated valves in the system allows more complex process steps to be simplified into an automated sequence. Automation enables precise and consistent operation and minimizes operator contact.

I Holland
Tablet-tooling coating improves punch and die performance

PharmaCote CX and CX+ (chromium nitride extra) tablet-tooling coatings from I Holland improve surface hardness, wear and corrosion resistance, and antisticking properties of punches and dies. The coating creates a smooth finish to help prevent tablet sticking, and multiple layers prolong tooling life. The new coatings offer up to 13 times more corrosion resistance than PharmaCote HC (hard chromium) and up to two times the life of PharmaCote CN (chromium nitride). The coating is also easy to clean and maintain using an ultrasonic bath and light, automated polishing.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here